Document is current
Any future updates will be listed below
-
Authors
Wahlström, Annika
Brumbaugh, Ariel
Sjöland, Wilhelm
Olsson, Lisa https://orcid.org/0000-0001-9730-1915
Wu, Hao
Henricsson, Marcus https://orcid.org/0000-0002-4202-0339
Lundqvist, Annika
Makki, Kassem
Hazen, Stanley L. https://orcid.org/0000-0001-7124-6639
Bergström, Göran https://orcid.org/0000-0003-4289-5722
Marschall, Hanns-Ulrich https://orcid.org/0000-0001-7347-3085
Fischbach, Michael A. https://orcid.org/0000-0003-3079-8247
Bäckhed, Fredrik https://orcid.org/0000-0002-4871-8818
-
Funding
Funding for this research was provided by:
Fondation Leducq (17CVD01)
Hjärt-Lungfonden (20210366)
Knut och Alice Wallenbergs Stiftelse (2017.0026)
Vetenskapsrådet (2019-01599)
AFA Försäkring (160337)
Novo Nordisk Fonden (NNF21OC0070298)
- License Information
-
More Information
Article History
Received: 8 December 2023
Accepted: 3 May 2024
First Online: 20 May 2024
Competing interests
: Stanford University and the Chan Zuckerberg Biohub have patents pending for microbiome technologies on which A.B. and M.A.F. are co-inventors. M.A.F. is a co-founder and director of Federation Bio and Kelonia, a co-founder of Revolution Medicines, and a member of the scientific advisory boards of NGM Bio and Zymergen. S.L.H. reports having received royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland Heart Lab, a fully owned subsidiary of Quest Diagnostics, and Procter & Gamble, being a paid consultant for Zehna Therapeutics, and having received research funds from Procter & Gamble, Pfizer Inc., Roche Diagnostics and Zehna Therapeutics. F.B. is co-founder and shareholder of Roxbiosens Inc and Implexion Pharma AB, receives research funding from Biogaia AB, and a member of the scientific advisory board of Bactolife A/S. The remaining authors declare no competing interests.
